Clinical vaccination studies in Ewing sarcoma
| Status | Phase | Type of vaccine | Antigen | Trial number |
| R | III | TC transfected with rhGM-CSF/RNAi bi-shRNAfurin+temozolimide | Autologous tumor cells | NCT03495921 |
| C | I | DC+adjuvant | NY-ESO-1, MAGEA1, MAGEA3 | NCT01241162 |
| C | III | DC+autologous T cells | EWS/FLI-1 | NCT00001566 |
| C | I | TC transfected with rhGM-CSF/RNAi bi-shRNAfurin | Autologous tumor cells | NCT01061840 |
| C | I | Antigen presenting cells (APC)+IL-2±autologous T cells | EWS/FLI-1 | NCT00001564 |
| C | I/II | DC+IL-7+autologous T cells | Tumor cell lysate | NCT00923351 |
| C | I | DC+decitabine | NY-ESO-1, MAGEA1 and MAGEA3 | NCT01241162 |
| C | II | TC transfected with rhGM-CSF/RNAi bi-shRNAfurin+temozolimide | Autologous tumor cells | NCT01241162 |
| C | I | Racotumomab anti-idiotype antibody | – | NCT01598454 |
| C | I | Peptide+adjuvant | MAGEA12 | NCT00020267 |
C, completed; DC, dendritic cells; IL, interleukin; R, recruiting; rhGM-CSF, recombinant human granulocyte macrophage-colony stimulating factor; TC, tumor cells.